GPCR News and Research

RSS

Study identifies new role of cholesterol in regulating brain proteins

A study led by researchers at the Hospital del Mar Medical Research Institute and the Institute of Medical Physics and Biophysics at the Faculty of Medicine in Charité Hospital, Berlin, published in the journal Nature Communications, demonstrates that the cholesterol present in cell membranes can interfere with the function of an important brain membrane protein, through a previously unknown mode of interaction.

23 Feb 2017

Researchers explore how G-protein-coupled receptors and arrestin form complexes

Researchers from Charité - Universitätsmedizin Berlin have been studying two proteins that play a vital role in many bodily processes.

23 Feb 2017

International scientists create first 3D atomic-level image of human cannabinoid receptor 1

In a discovery that advances the understanding of how marijuana works in the human body, an international group of scientists, including those from the Florida campus of The Scripps Research Institute (TSRI), have for the first time created a three-dimensional atomic-level image of the molecular structure activated by tetrahydrocannabinol (THC), the active chemical in marijuana.

24 Oct 2016

Scientists use new technique to improve accuracy of detecting protein microcrystals

In a collaborative study, scientists from MIPT and JINR (Joint Institute for Nuclear Research) have increased the accuracy of detecting valuable protein crystals measuring just a few microns.

20 Oct 2016

Domain Therapeutics and Medicxi partner to launch Mavalon Therapeutics

Domain Therapeutics, a biopharmaceutical company that specializes in the discovery and development of G protein-coupled receptor (GPCR) drugs, today announces the creation of Mavalon Therapeutics, a company focused on stopping the progression of Parkinson’s disease.

19 Oct 2016

Researchers use unique computational approach to identify promising drug leads for heart diseases

Using a unique computational approach to rapidly sample, in millisecond time intervals, proteins in their natural state of gyrating, bobbing, and weaving, a research team from UC San Diego and Monash University in Australia has identified promising drug leads that may selectively combat heart disease, from arrhythmias to cardiac failure.

6 Sep 2016

Gentle combination of FDA-approved drugs could combat photoreceptor degeneration in mice

In microseconds, every light ray that enters the eye triggers an explosion of coordinated cellular events.

29 Aug 2016

Combinations of FDA-approved drugs may prevent vision loss linked to retinal degeneration

Combinations of Food and Drug Administration-approved drugs protect against the loss of cells required for vision in a mouse model of blinding retinal diseases.

4 Aug 2016

GPCR-Gβγ inhibition therapy could prevent chronic and acute kidney damage in heart failure patients

A study in the Journal of the American Society of Nephrology suggests a new therapeutic approach to treat the development of chronic kidney disease secondary to chronic heart failure, known as cardiorenal syndrome type 2.

14 Jun 2016

Researchers use BMG LABTECH's microplate readers to measure binding events in kinetic over minutes

Single reading events of a signaling molecule at a given time should no longer be considered as the only insightful indicator to predict the usefulness of a new drug candidate.

From BMG LABTECH GmbH 19 Apr 2016

Versatile Automated Microplate Sample Screening Applications

In this interview, News Medical speaks Tobias Pusterla, Ph.D from BMG Labtech about versatile automated microplate sample screening applications.

From BMG LABTECH GmbH 30 Mar 2016

Researchers find new innate immunity pathway that protects mammals from viral oncogenesis

Building upon earlier research, investigators at UT Southwestern Medical Center and their collaborators have identified a new innate immunity pathway that protects mammals from viral oncogenesis, the process by which viruses cause normal cells to become cancerous.

14 Mar 2016

Researchers discover unexpected mechanism linked to aldosterone-induced heart damage

When the heart begins to fail, the body does everything in its power to fix the situation. But sometimes, those compensatory mechanisms ultimately do more harm than good. Such is the case with the adrenal hormone aldosterone, which stimulates the heart to pump harder, causing greater damage to the heart muscle.

3 Mar 2016

Polyunsaturated lipids can alter binding rate of two receptors involved in Parkinson's and Alzheimer's

A study published in the prestigious journal Scientific Reports from the Nature group demonstrates, for the first time and using computational tools, that polyunsaturated lipids can alter the binding rate of two types of receivers involved in certain nervous system diseases.

2 Mar 2016

Larger crystals of bacteriorhodopsin protein grow by consuming smaller crystals around them

A group of biophysicists from Moscow Institute of Physics and Technology and their international colleagues have studied the crystallization of molecules of the membrane protein bacteriorhodopsin. The scientists have demonstrated that the larger crystals of the protein grow by "consuming" smaller crystals around them and creating "depletion zone" around themselves.

12 Dec 2015

TSRI scientists use new drug discovery technique to identify anti-diabetes compound

Scientists from The Scripps Research Institute have deployed a powerful new drug discovery technique to identify an anti-diabetes compound with a novel mechanism of action.

8 Dec 2015

Heptares announces strategic drug discovery collaboration with Pfizer

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, announces that it has entered into a strategic drug discovery collaboration with Pfizer Inc. to research and develop potential new medicines directed at up to 10 G protein-coupled receptor (GPCR) targets across multiple therapeutic areas.

30 Nov 2015

Heptares, AstraZeneca sign licensing agreement to develop and commercialise immuno-oncology treatments

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, is pleased to announce that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.

6 Aug 2015

G7 Therapeutics, MorphoSys collaborate on novel antibody therapeutics targeting GPCRs and ion channels

MorphoSys AG and G7 Therapeutics AG announced today that they have signed an agreement to collaborate on novel antibody therapeutics targeting G protein-coupled receptors and potentially other disease-related transmembrane proteins such as ion channels.

4 Aug 2015

Atomic level images reveal how neuropeptide hormone neurotensin may activate its receptors

Many hormones and neurotransmitters work by binding to receptors on a cell's exterior surface. This activates receptors causing them to twist, turn and spark chemical reactions inside cells.

3 Aug 2015